share_log

Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115

Morgan Stanley Upgrades Axsome Therapeutics to Overweight, Raises Price Target to $115

摩根士丹利將Axsome Therapeutics上調至增持,將目標股價上調至115美元
Benzinga ·  04/29 05:27

Morgan Stanley analyst Vikram Purohit upgrades Axsome Therapeutics (NASDAQ:AXSM) from Equal-Weight to Overweight and raises the price target from $90 to $115.

摩根士丹利分析師維克拉姆·普羅希特將Axsome Therapeutics(納斯達克股票代碼:AXSM)從等重上調至增持,並將目標股價從90美元上調至115美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論